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Malaria burden is heavily concentrated in sub-Saharan Africa (SSA) where cases and deaths 
associated with COVID-19 are rising1. In response, countries are implementing societal measures 
aimed at curtailing transmission of SARS-CoV-22,3. Despite these measures, the COVID-19 epidemic 
could still result in millions of deaths as local health facilities become overwhelmed4. Advances in 
malaria control this century have been largely due to distribution of long-lasting insecticidal nets 
(LLINs)5, with many SSA countries having planned campaigns for 2020. Here, we use COVID-19 and 
malaria transmission models to estimate the impact of disruption of malaria prevention activities 
and other core health services under four different COVID-19 epidemic scenarios. If activities are 
halted, the malaria burden in 2020 could be more than double that of 2019. In Nigeria alone 
reducing case managment for 6 months and delaying LLIN campaigns could result in 81,000 (44,000–
119,000) additional deaths.  Mitigating these negative impacts is achievable, and LLIN distributions 
in particular should be prioritised alongside access to antimalarial treatments to prevent substantial 
malaria epidemics.  
 
Globally, COVID-19 has the potential to overburden health systems. Interventions aimed at curbing 
transmission of SARS-CoV-2, such as restrictions to movement, absenteeism, behavioural changes, 
closure of institutions and interruption of supply chains, are also expected to result in malaria 
prevention activities being scaled back6,7. These anti-malarial activities include mass distribution of 
long-lasting insecticidal nets (LLINs), which are the most effective current tool for reducing malaria5. 
LLINs are typically distributed centrally within a community at gatherings that could be cancelled or 
poorly attended as COVID-19 spreads. Other important focal preventative measures, such as seasonal 
malaria chemoprevention (SMC) and indoor residual spraying of insecticide (IRS), which are conducted 
house-to-house, could also be reduced. The World Health Organization (WHO) has emphasized that 
all routine prevention and case management activities should be continued to the fullest extent 
possible8; however, early statistical modelling suggests that disrupting LLIN distribution and malaria 
treatment could have substantial impact on malaria burden in Africa6.  
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Here, we attempt to quantify the potential impact of the spread of COVID-19 on Plasmodium 
falciparum malaria morbidity and mortality in Nigeria and across sub-Saharan Africa using 
mathematical models of COVID-199 and malaria10. We assume that one disease does not directly 
influence the transmission or severity of the other, but that COVID-19 impacts malaria via the 
response to the epidemic and its repercussions on health systems. Predictions of the timing and 
magnitude of COVID-19 epidemics across African countries are highly uncertain and will vary according 
to how individual countries respond to COVID-19. We use illustrative examples to show how different 
COVID-19 mitigation and suppression strategies could influence malaria burden. A summary of the 
main findings, limitations and policy implications of our study is shown in Table 1. The pervasive and 
potentially large consequences of COVID-19 on African communities, such as increased poverty, 
malnutrition and social instability, which themselves can influence malaria burden, are not captured. 
We consider four scenarios for the COVID-19 epidemic which will determine the period of malaria 
service interruption (Figure 1): 1) Unmitigated COVID-19 epidemic – whilst unlikely to occur this 
scenario illustrates how a rapid epidemic would be highly disruptive to malaria services but for a 
limited period; 2) Mitigation – social contact is reduced but the effective reproduction number (Rt) 
remains above 1 causing a longer-lasting COVID-19 epidemic; 3) Suppression – social distancing 
reducing Rt<1 remains in place until alternative strategies to contain COVID-19 are available with 
malaria activities potentially disrupted for a year; 4) Suppression lift – suppression is sustained but 
then subsequently lifted resulting in a resurgence of the COVID-19 epidemic.   
We assume that malaria services could be interrupted if COVID-19 mitigation or suppression activities 
are ongoing or if health care capacity is exceeded due to COVID-19. The impact of different levels of 
malaria service interruption are investigated. LLIN campaigns can either continue as normal or be 




Presently, it is unclear how COVID-19 will spread in Africa, although all four COVID-19 scenarios are 
projected to result in substantial additional deaths from malaria. Implementing COVID-19 mitigation 
strategies substantially reduces COVID-19 mortality but the prolonged period of health system 
disruption risks considerably increased malaria deaths (Table 2). This is especially evident in Nigeria 
where the longer malaria service disruption due to a mitigated (for 6 months) or suppressed (for 1 
year) COVID-19 epidemic overlaps with the malaria transmission season, which peaks around 
September (Figure 1). Considering the effect of the COVID-19 mitigation scenario across SSA over the 
coming year, if SMC and IRS were halted, the treatment of clinical cases was reduced by half for the 
next 6 months from 1 May 2020, and LLIN campaigns due in 2020 were cancelled, malaria cases are 
estimated to increase by 206 million (95% Uncertainty Interval, UI, 157–254 million) (Supplementary 
Table 1), and malaria deaths by 379,300 (95% UI 221,400–537,300) (Table 2), with a corresponding 
additional 19 (95% UI 11–26) million life-years lost (Supplementary Table 2).  
Many countries are pursuing strategies to suppress COVID-19 to minimise deaths1. Our results 
illustrate that even if COVID-19 suppression is well-managed and LLIN campaigns remain unaffected, 
with SMC coverage and case management reduced by 50% relative to the norm, prolonged service 
interruption could increase malaria deaths in Nigeria by approximately 42,300 (95% UI 22,200–62,300) 
(Supplementary Table 3) and across SSA by 200,000 (95% UI 114,700–285,200) (Table 2). The impact 
of disruption to malaria services lasting 6 months or more from 1 May 2020 will be greatest in 
countries where the malaria transmission is high at the end of the year (Supplementary Figure 1). 
Failure to maintain a COVID-19 suppression strategy is likely to lead to a large resurgence potentially 
resulting in worse outcomes for both COVID-19 and malaria.  
Our findings demonstrate that provision of LLINs is critical. Twenty-seven of the 47 malaria-endemic 
countries in SSA were due LLIN campaigns in 2020, with delivery of 228 million LLINs expected 
(https://netmappingproject.allianceformalariaprevention.com/). Across SSA, maintaining routine 
LLIN distribution in a COVID-19 mitigation scenario is predicted to halve deaths attributable to malaria 
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(Table 2). This year, many LLINs in SSA will be three years old and have diminished efficacy due to 
insecticide loss and physical degradation11. The increased spread of mosquitoes resistant to LLIN 
insecticides may exacerbate this problem12. Effects can vary substantially within countries according 
to existing LLIN protection and whether the COVID-19 epidemic will delay scheduled LLIN campaigns 
(Figure 2A, Supplementary Figure 2).  
Disruption to case management increases the case fatality ratio (Supplementary Table 4) and is 
predicted to have a similar effect on morbidity to cancelling LLIN campaigns if services are stopped for 
equivalent time periods (illustrated in the COVID-19 suppression scenario when both LLIN and clinical 
treatment are interrupted for one year, Table 2). Maintaining 50% of the normal level of treatment 
over a 6-month period could still prevent up to 100,000 deaths if prevention activities ceased. In 
Nigeria, case management was estimated to be particularly important due to mass LLINs campaigns 
scheduled in just 7 of the 37 states in 2020. SMC is currently implemented in the Sahel region of West 
Africa, which reduces the continental effects of this anti-malarial activity. However, the consequences 
of cancelling SMC in operational regions is predicted to be large. A successful 2020 SMC campaign (in 
regions covered in 2019) is predicted to reduce deaths by 40% in a COVID-19 mitigation scenario if 
LLIN distributions and case management are also halted (Supplementary Table 5).   
There is considerable uncertainty in how COVID-19 will spread in Africa and how countries will 
respond2,13. A lower basic reproduction number, R0, would slow the epidemic and reduce COVID-19 
deaths, yet potentially increase malaria mortality as a result of prolonged anti-malarial service 
interruption. Social-distancing measures may reduce the spread of COVID-19 in Africa, it is unclear 
how long these measures will be maintained for and what their effects on healthcare capacity will be 
(Supplementary Figure 3). This uncertainty substantially influences not only estimates of COVID-19 
mortality but also the interruption of malaria services. For example, in Nigeria, if COVID-19 spreads 
with an R0 of 2.5 compared to 3, service interruption in the COVID-19 mitigation scenario would be 
extended from 6 to 9 months to prevent a resurgence of COVID-19 (Supplementary Figure 3), which 
7 
 
would increase malaria deaths by ~17% even if LLINs were distributed and some case management 
was maintained (Supplementary Table 6). Overall, the effects of COVID-19 on malaria are predicted to 
be greater than early estimates by the WHO6. This is likely due to the inclusion of SMC and IRS in our 
analysis, which have substantial public health impact. The model also mechanistically captures 
differences in population immunity (determined by the history of malaria infection) and the impact of 
insecticide-resistant mosquitoes, both of which could increase malaria resurgence. Nevertheless, the 
numbers of deaths presented here should be considered illustrative as there are large uncertainties 
in how COVID-19 will spread and communities respond. 
Following the 2014 West African Ebola crisis, the WHO now recommends the use of mass drug 
administration (MDA) to prevent excess mortality during complex emergencies14. We explored the 
extent to which introducing or extending chemoprevention could mitigate excess malaria deaths 
during the COVID-19 epidemic. If LLIN campaigns in 2020 are delayed during a mitigated COVID-19 
scenario, increasing the target age of SMC across the Sahel region from children under 5 years to 
children under 10 and 15 years could save 13,500 and 22,400 lives, respectively (Figure 2B, 
Supplementary Figure 4A, Supplementary Table 7). Almost half of the lives saved would be in Nigeria 
SMC regions (Supplementary Table 8). Outside current SMC areas, a single round of MDA to 70% of 
the population is predicted to avert up to 266 deaths per million people over the next year 
(Supplementary Figure 4B, Supplementary Table 9) depending on the region in which it is 
implemented (Supplementary Figure 4B, 5 and Supplementary Table 10). Such emergency measures 
will depend on the feasibility of increasing the supply of appropriate drugs in areas where SMC 
interventions are not currently planned.  
Symptoms of both COVID-19 and malaria include fever, which can confuse diagnosis in settings with 
limited testing for both diseases. In COVID-19 cases, the likelihood of developing fever increases with 
age (Figure 3A), whereas malaria fever declines with age. The percentage of fevers attributable to 
malaria compared with COVID-19 is predicted to vary temporally according to the synchrony of the 
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two epidemics (Figure 3B-C). Further, the proportion of febrile children in whom fever is attributable 
to malaria is likely to be higher than shown in our results, due to the data on COVID-19 fever in children 
primarily being sourced from hospital settings (Supplementary Data 1).  Many countries are advising 
that suspected COVID-19 cases should self-isolate (https://www.acaps.org/covid19-government-
measures-dataset) which  might further reduce malaria diagnosis. Providing simple age-based 
guidelines could substantially reduce malaria burden if malaria tests are unavailable. For example, 
presumptively treating 70% of febrile children under 5, 10 and 15 years with antimalarials could save 
122,000, 159,000 and 178,000 lives over the next year, respectively. Further work is needed to 
consider the implications of this strategy on the supply of drugs and burden of non-malarial fevers15. 
Adhering to social-distancing guidelines will also remain critical as many people who are infected with 
COVID-19 could also harbour malaria parasites. For example, our modelled results indicate that at the 
malaria transmission season peak in Mali (an example of a country with seasonal transmission, Figure 
3B), in individuals older than 15 years, 30% of those infected with COVID-19 would also have malaria 
parasites, and therefore may not self-isolate if diagnosed with malaria as the cause of their fever. 
The rapid global spread of the SARS-CoV-2 virus has demonstrated the global vulnerability to new 
infectious diseases. Continued malaria prevention and treatment programs will be essential to reduce 
pressure on health systems during the COVID-19 pandemic. 
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Table 1: Policy summary 
 
Background The COVID-19 pandemic and the measures put in place to reduce its spread 
could severely impede malaria prevention activities such as bed net 
distribution as well as reduce access to malaria treatment if health systems 
become overwhelmed. We use transmission dynamics models of COVID-19 
and malaria to investigate how different levels of malaria service 
interruption could influence malaria disease control and deaths in sub-
Saharan Africa, which accounts for more than 90% of malaria deaths 
globally, and disproportionately affect children.  
Main findings and 
limitations 
If malaria control activities are severely disrupted as a result of the COVID-
19 pandemic, we find that malaria deaths could more than double in 2020 
compared to 2019. If mosquito nets are not deployed and case 
management is reduced by half for 6 months there could be 779,000 
malaria deaths in sub-Saharan Africa over 12 months.  The projected effect 
varies according to how long services are interrupted, if the disruption 
coincides with the malaria transmission season and whether routine vector 
control interventions such as the mass distribution of mosquito nets were 
due in 2020. Reducing malaria transmission has additional benefits in 
reducing the presentation of fever cases in the health system at a time 
when they may be overwhelmed with COVID-19 cases. The projected effect 
on malaria services and mortality is highly uncertain as these estimates are 
heavily dependent on how countries respond to the COVID-19.  
Policy implications Swift action now could substantially reduce the burden of malaria and 
prevent joint malaria and COVID-19 epidemics simultaneously 
overwhelming vulnerable health systems. Routine distributions of mosquito 
nets should be prioritised alongside increasing access to antimalarial 




Table 2. Projected COVID-19 and additional malaria deaths between 1 May 2020 and 30 April 2021 for 
different COVID-19 scenarios in malaria-endemic countries in sub-Saharan Africa. Different combinations of 
malaria interventions are considered on each row, with the colour denoting whether they were halted for the 
period of health system interruption (red), reduced to 50% of the normal coverage level (light green) or 
continued as normal (dark green). LLINs = distribution of long-lasting insecticidal nets in countries due for mass 
campaigns in 2020, SMC = seasonal malaria chemoprevention in SMC target areas in the Sahel region and, 
Treatment = treatment of clinical cases. LLINs and SMC campaigns are only disrupted in regions where they were 
previously planned.  Malaria scenario numbers correspond to those plotted in Supplementary Figure 1 and 
Figure 2. The point estimate of deaths due to COVID-19 is from the assumption of an R0 of 3.0, with ranges in 
brackets showing 95% uncertainty interval (95% UI). Additional malaria deaths are shown as the point estimate 
and 95% UI rounded to the nearest thousand. 
  COVID-19 scenario 
  Unmitigated Mitigation Suppression Suppression 
lift 




5,923 (2,892 – 
11,028) 
0.4 (0.3 - 4.5) 7,374 (3,223.5 
– 14,024) 
Malaria scenario Additional malaria deaths (‘000) (95% UI) 
(compared to a baseline estimate of 422 (95% UI 225–619) deaths in 
this period without malaria service interruption)   
No. LLINs SMC Treatment 
1    239 (140–337) 379 (221–537) 464 (277–651) 380 (222–539) 
2    221 (131–312) 282 (167–397) 322 (195–450) 282 (167–397) 
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3    26 (15–38) 112 (61–163) 200 (115–285) 112 (61–164) 
4    39 (21–57) 184 (98–270) 314 (175–453) 186 (99–272) 
5    41 (23–58) 129 (71–186) 189 (107–270) 130 (71–188) 
6    220 (128–311) 357 (207–507) 495 (296–693) 358 (207–509) 
7    25 (13–37) 164 (86–241) 310 (174–446) 165 (87–243) 
8    55 (30–79) 205 (110–300) 336 (189–484) 207 (111–302) 
9    238 (139–337) 461 (263–659) 696 (413–979) 464 (265–662) 
10    219 (127–311) 434 (247–622) 668 (396–940) 437 (249–625) 
11    253 (148–357) 481 (277–686) 695 (413–978) 484 (278–690) 
 
 
Figure 1. Projected deaths due to COVID-19 and malaria in Nigeria over time for different COVID-19 scenarios. The 
top row shows the COVID-19 epidemic and the number of people needing oxygen support per week for four different 
COVID-19  scenarios – an unmitigated epidemic (red), mitigation (blue), continued suppression (green) and 
suppression lift (purple). The thin dotted horizontal grey line indicates estimated healthcare capacity for a typical 
African country. The thick black horizontal line beneath each figure shows the period when COVID-19 mitigation or 
suppression activities are assumed in operation. The upper middle row indicates the assumed duration of interruption 
where COVID-19 interventions affect different malaria prevention activities (IRS = indoor residual spraying, LLINs = 
mass distribution of long-lasting insecticidal nets, SMC = seasonal malaria chemoprevention) or case management of 
clinical cases with the level of this disruption presented in Table 2. The lower middle row shows the predicted deaths 
due to COVID-19 per week in each scenario. The bottom row shows predicted malaria deaths per week for each 
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scenario (coloured lines) and for the counter-factual where there was no COVID-19 induced disruption (black lines). 
The top coloured lines indicate a scenario where nets and SMC are ceased and case management reduced by half 
(Supplementary Table 3, row 1) whereas the bottom dashed coloured lines show the most well-managed scenario 




Figure 2. Number of additional deaths due to malaria in different regions of sub-Saharan Africa (SSA) and the impact of expanding existing seasonal malaria 
chemoprevention (SMC) and mass drug administration (MDA) in a COVID-19 mitigation scenario. (a) Estimated additional deaths per million people when all malaria 
interventions (LLIN campaigns, SMC and clinical treatment of cases) are ceased for 6 months relative to normal service in the absence of COVID-19 for each administrative 
region (maps for other COVID-19 scenarios are presented in Supplementary Figure 2). (b) Reduction in additional malaria deaths by expanding the age of those eligible for 
SMC in regions within the Sahel where it was conducted in 2019 relative to all malaria interventions cancelled (Table 2, row 11: red bars) or LLIN distributions continue whilst 
clinical treatment ceases (Table 2, row 8: blue bars). Absolute values are shown in Supplementary Table 7. (c) Reduction in additional malaria deaths by introducing a single 
round of MDA (using the prophylactic with a similar profile to Amodiaquine plus sulfadoxine-pyrimethamine) for regions where SMC is not currently conducted 
(Supplementary Table 9). MDA is assumed implemented at the optimal time, prior to the transmission peak for each administration unit. In both SMC and MDA scenarios, 
we assume that 70% of the respective populations receive the intervention. Negative values indicate there are fewer malaria deaths than would have been predicted if 




Figure 3. How fever symptoms of COVID-19 and malaria may influence diagnoses. (a) A systematic review of the literature showing how the percentage of COVID-19 cases 
with fever varies with respect to age. Points show published estimates coloured according to the cohort they were observed in: patients admitted to hospital (red), intensive 
care units (ICU, green), contacts of known cases (blue) or a mixed cohort (purple). A summary of all data including precise estimates and sample sizes for each study are 
provided in Supplementary Table 13. Solid line shows best fit logistic regression line fit to all groups, shaded region indicates 95% confidence interval estimates in the mean. 
Vertical coloured lines show the interquartile range for the proportion of fevers (when available) whilst the horizontal coloured lines show the range of ages reported in each 
cohort. (b) Left column figures show estimates of how the proportion of malaria fevers relative to COVID-19 fevers (i.e. proportion of fevers due to malaria divided by malaria 
plus COVID-19 fevers) varies over time; right column shows the proportion of COVID-19 cases co-infected with asymptomatic malaria. Top row shows predictions for seasonal 
Mali; bottom row shows more perennial Uganda. In all panels in (b), black lines indicate prevalence of malaria (as detected by microscopy), and dashed lines show COVID-19 
prevalence; coloured lines indicate age of group in years, either 0–5 (red), 5–15 (green) or greater than 15 (blue) years of age (scaling COVID-19 fevers by age using the 
regression line presented in (a)). Panel (c) shows country-level mean estimates of the fraction of fevers due to malaria compared to those due to malaria and or Covid-19 in 
children under 5 years in July 2020.
16 
 
Online methods  
COVID-19 transmission model 
Potential COVID-19 trajectories were produced through a modelling framework from Walker et al9. 
We used an age-structured SEIR model of transmission with age-specific patterns of disease severity 
captured according to age-dependent probabilities that infection leads to disease requiring 
hospitalisation (and the need for treatment with high-pressure oxygen), to more severe disease 
requiring intensive care and subsequently to mortality. Model parameters are based on analysis of 
age-specific severity and infection-mortality ratios observed in China and the UK9,16,17 since 
comparable data from sub-Saharan Africa are currently not available. To produce simulations 
representative of a malaria endemic setting, the model was calibrated to typical social contact 
patterns observed within surveys in sub-Saharan Africa (SSA), which show less substantial declines in 
contact rates by age18, and the demography of Nigeria, our case study and the country with the highest 
burden of malaria globally19. Our projections therefore incorporate a lower per-infection demand for 
healthcare such as oxygen and mechanical ventilation driven by the younger populations within 
malaria endemic settings. Life-years lost were calculated under this demography using the 
corresponding life tables. 
To capture the likely constraints within a health system, we contrasted this demand for healthcare 
with a representative level of supply using the median estimated provision of hospital beds and 
intensive care units for a low-income country9. This threshold was chosen on the basis that, although 
many countries in SSA are lower-middle-income and therefore likely to have a lower total number of 
hospital beds and intensive care units, access to high pressure oxygen and mechanical ventilation 
within hospitals is lower than within equivalent high income settings20. During the course of a 
projected scenario, as healthcare capacity is exceeded, individuals requiring either mechanical 
ventilation or high pressure oxygen who are unable to receive these interventions are then subject to 
a substantially higher degree of mortality, leading to excess mortality during time-periods in which 
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health systems are overwhelmed (for full details, code and parameterisation see 
https://github.com/mrc-ide/squire (accessed June 09, 2020)).  
Representative scenarios were simulated using a basic reproduction number, R0, of 3 representing a 
3.5 day doubling time in cases and deaths reflective of many trajectories currently observed globally21. 
A full list of the parameter values is provided in Supplementary Table 11. Once a threshold of 0.1 
deaths per million (approximately reflecting the COVID-19 mortality observed in many countries in 
Africa to date) is exceeded, the pandemic trajectory follows four potential scenarios:  
• “Unmitigated”: no direct action is taken but contact rates are reduced by 20% relative to baseline 
according to assumed behaviour change given the pandemic even in the absence of specific, 
coordinated public health interventions. 
• “Mitigation”: through combinations of isolation and social distancing, contact rates are reduced 
by 45% for 6 months after which infections fall to low levels and contact rates return to pre-
pandemic levels. This scenario approximates the maximum reduction in the final size of the 
epidemic that can be achieved whilst generating sufficient levels of immunity capable of 
preventing a second wave once measures are lifted (assuming infection leads to high levels of 
immunity from reinfection). It thus produces the lowest final numbers of COVID-19 infections of 
the three strategies that do not involve indefinite suppression.  
• “Indefinite suppression”: stringent suppression-targeting interventions are implemented to 
reduce contact rates by 75%, and these are maintained indefinitely in the hope that a 
pharmaceutical intervention (e.g. effective vaccine) is developed and deployed. We run this 
scenario for 12 months. (After this period, lifting suppression without such a pharmaceutical 
intervention would lead to a second wave of equivalent size as in the “Suppression lift scenario”.) 
• “Suppression lift”: the stringent ‘lockdown’ type interventions implemented by many countries 
are assumed to reduce contact rates by 75%. This reduction is maintained for two months, then 
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lifted, and contact rates return to 80% of their pre-pandemic levels for the remainder of the 
epidemic.  
These scenarios represent four possible projections of what could happen to the epidemic, not what 
policy strategy was adopted by the different countries. The number of deaths associated with COVID-
19 between 1 May 2020 to 30 April 2021 is estimated for African populations at risk of malaria to 
provide a direct comparison with the predictions of malaria mortality.  
It is assumed that malaria control is impeded by either the health system being overwhelmed or 
because mitigation or suppression social distancing measures are in place. The health system is 
classified as being overwhelmed when the model estimates that the number of people currently 
requiring non-critical care in hospitals for COVID-19 is 50% more than current hospital capacity (here 
defined for Africa as 1,281 per million people9). The timing and duration of service interruption for the 
different COVID-19 scenarios are shown in the second row of Supplementary Figure 1. 
The trajectory of the COVID-19 pandemic in Africa is highly uncertain. To illustrate this uncertainty 
two different sensitivity analyses are conducted; (i) a univariate sensitivity analysis which shows how 
R0 influences the severity of the epidemic, and (ii) a multivariate sensitivity analysis which varies all 
parameters to indicate the wider uncertainty. 
In the univariate sensitivity analysis we vary R0 between 2.0 and 3.5 to cover the range of estimates 
currently predicted for the region2,13. This is repeated for the 4 different COVID-19 scenarios described 
above. Estimates of the number of people requiring supplementary oxygen over time are presented 
in Supplementary Figure 3A. Note that in the COVID-19 mitigation scenario when R0 is lower than 3 
the epidemic is not predicted to have peaked after 6 months when the social distancing measures are 
assumed to be lifted (and many people have not been infected). In this scenario, if social distancing 
measures are relaxed then there is predicted to be a large rebound epidemic with a high death rate 
as hospitals are overwhelmed (similar to the suppression lift scenario). This means that lower R0 
simulations may counter-intuitively have higher deaths due to COVID-19. An alternative assumption 
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could be that social distancing measures in the mitigation scenario are extended for 9 or 12 months. 
These simulations indicate a lower peaked epidemic with fewer deaths. Both possible mitigation 
scenarios with different periods of social distancing are presented in Supplementary Figure 3A. 
In the multivariate sensitivity analysis we vary all the main parameters within the model for the 4 
different COVID-19 scenarios. These include R0, the effectiveness of social distancing at reducing the 
contact rate, parameters determining the duration of hospitalisation and the different severity 
parameters of the disease (the probability of death if critical care is required but not received; 
probability of death if hospitalised and oxygen is available; probability of death if hospitalised and but 
oxygen is not available and probability of death if hospitalisation is required by no hospital bed is 
available). A total of 500 parameter draws were independently sampled using a log-scaled triangular 
distribution centred around 1 which spanned the range of values presented in Supplementary Table 
11. To capture uncertainty in the infection fatality ratio (IFR) and how this varies by age, the 
probabilities of death reported in Supplementary Table 11 were applied to 500 posteriors sampled 
from the fitted joint posterior distribution from Verity et al13. This provides 500 different estimates of 
the magnitude of the IFR and how it increases with age. These values were then used to parameterise 
500 different simulations of COVID-19 transmission model. For each run the period of potential 
malaria service interruption were calculated from the introduction of mitigation measures to the time 
when healthcare is non-longer over capacity (Supplementary Figure 3B-E). Results show how varying 
the parameters of the COVID-19 mitigation scenario can produce COVID-19 trajectories similar to the 
other three COVID-19 scenarios considered. For example, a high R0 generates short periods of service 
interruption similar to the unmitigated scenario whilst a low R0 may recreate the period of interruption 
of either the suppression lift scenario (if social distancing measures are released after 6 months) or a 
suppression scenario (if social distancing is maintained for a longer period). The uncertainty in the 
number of deaths from the multivariate sensitivity analysis were used to estimate the mortality 95% 




Malaria transmission model 
A previously published model of malaria transmission dynamics was used to predict malaria deaths 
resulting from different COVID-19 scenarios10 (code is freely available 
https://github.com/jamiegriffin/Malaria_simulation). Simulations were run at the administrative 1 
unit level (where, for each region, the model is calibrated to capture the seasonality, prevalence, 
vector composition, treatment coverage and vector control coverage incorporating levels of 
pyrethroid resistance in each unit) and results are aggregated across regions according to size of the 
population at risk of malaria. Results are presented for the high malaria burden country of Nigeria and 
for SSA as a whole. For Nigeria, administrative 1 unit level estimates of malaria prevalence, long-lasting 
insecticidal net (LLIN) use, drug treatment, coverage of seasonal malaria chemoprevention (SMC) and 
the timing of 2020 LLIN campaigns were made available by the National Malaria Elimination 
Programme (NMEP) in Nigeria (Supplementary Figure 6). For other regions of SSA models were 
parameterised using 2016 malaria prevalence from the Malaria Atlas Project (MAP, 
https://malariaatlas.org/ (accessed September 10, 2018)). For all countries, modelled clinical cases 
were aligned with World Malaria Report median cases.19,22 LLIN usage was estimated at the 
administrative 1 unit level also using MAP estimates, with LLIN usage after campaigns expected to be 
matched at each subsequent mass campaign. Malaria control depends on insecticide resistance in the 
local mosquitoes which diminishes the effectiveness of LLINs. This was estimated for each 
administrative unit from discriminating dose bioassays collated by the World Health Organization over 
time (projecting forward to 2020) and combined with results from experimental hut trials to estimate 
the LLINs epidemiological impact23,24. Malaria transmission seasonality was estimated by local rainfall 
trends averaged over eight years and offset by 35 days to reflect mosquito abundance (National 
Weather Service. Climate Prediction Center. [internet] (cited 24 Mar 2016)25,26). The estimated 
proportion of clinical cases receiving prompt treatment was based on Demographic Health Survey 
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(DHS) data and is assumed to remain at estimated 2016 levels27. Malaria deaths across all ages were 
estimated using the modelled number of severe cases, scaled by the assumed proportion of severe 
cases resulting in mortality both in and outside the hospital setting, and adjusted by the location-
specific proportion of clinical cases receiving treatment10. Estimates of malaria deaths in 2018 were 
scaled to align with World Malaria Report median deaths for 2018 for the same region19. 
Different levels of malaria prevention and treatment interruption are considered together. The impact 
of the COVID-19 epidemic on malaria is determined solely by the durations of service interruption 
which vary for malaria prevention and treatment activities according to which of the four different 
COVID-19 scenarios is considered. The duration of these different periods of interruption of malaria 
services are presented in Figure 1 and are chosen to be representative of the range of durations 
observed in the multivariate sensitivity analysis of the COVID-19 model (Supporting Figure 3D). We 
assume that changing the human-to-human contact rate that influences the trajectory of the COVID-
19 epidemic has no impact on malaria transmission other than through the duration of service 
interruption. The possible impact of COVID-19 on LLIN distribution is assumed to start at the beginning 
of the COVID-19 epidemic as the majority of African countries initiated some mitigation or suppression 
activities. The increase in malaria cases caused by COVID-19 will depend on the time since the last 
LLIN campaign, as older nets are likely less effective due to loss of insecticide24. Aging of LLINs may be 
exacerbated by the spread of insecticide resistant mosquitoes, as they may overcome the 
concentrations of insecticide on the LLIN earlier than susceptible mosquitoes12,24. All LLINs prior to 
2020 are assumed to be standard pyrethroid-only LLINs, as the numbers of alternative LLINs procured 
in 2019 are very low. In Nigeria the year and month of LLIN campaigns is known (or approximated for 
future mass distributions) at the administrative 1 unit level (state) providing greater resolution. For 
elsewhere in Africa Alliance for Malaria Prevention 
(https://netmappingproject.allianceformalariaprevention.com/) estimates were used to calculate the 
timings of campaigns and the proportion of LLINs distributed in 2018, 2019 and due in 2020 by country 
as it is unclear when or where the different campaigns were delivered at a sub-national level. Different 
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simulations were run for each administrative unit distributing LLINs at the appropriate year and 
season. Overall estimates of clinical cases in the administrative unit were weighted by the proportion 
of LLINs given out that year. LLIN campaigns due to occur prior to April 2020 were assumed to have 
occurred as planned. Those campaigns which were due at a time of COVID-19 induced-disruption 
either went ahead as planned (achieving the same population coverage) or were delayed until a year 
after they were originally due. LLIN campaigns due in quarters 2–4 in 2020 were assumed to be 
delayed in the unmitigated, mitigated and suppression lift COVID-19 scenarios. This period of 
disruption is assumed to be longer than other control interventions, reflecting the high chance of 
disruption to the LLIN supply chain and difficulties in distributing LLINs to local communities.  Standard 
pyrethroid LLINs were distributed in 2020 unless the region was due to have LLINs with the synergist 
piperonyl butoxide, and LLIN efficacy estimates were taken from Churcher et al24. It is assumed that 
80% of LLINs are distributed through mass campaigns and the remaining are distributed continually, 
and that these continual distributions cease if LLIN mass campaigns are delayed.  
Uncertainty in the estimated number of clinical cases and deaths and life-years lost was investigated 
using a multivariate sensitivity analysis. It was not computationally possible to generate full posterior 
samples for all scenarios presented here. We therefore developed and tested a Normal approximation 
to the posterior distribution for the output metrics.  
First, twenty draws from the joint posterior distribution of the fitted transmission model parameters 
were used to generate 20 uncertainty runs for all 37 states in Nigeria, for each of the COVID-19 and 
malaria scenarios (Supplementary Figure 7). For each uncertainty run, we calculated the additional 
clinical cases and deaths to generate 95% uncertainty intervals for Nigeria, and also calculated the 
coefficient of variation (CoV). We then tested the applicability of a Normal approximation for 
uncertainty in other regions by undertaking a full uncertainty analysis across a smaller subset of 40 
first administrative units (10 administrative units from each of Zambia (all provinces included), 
Mozambique, Democratic Republic of the Congo and Burkina Faso) and comparing 95% uncertainty 
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intervals generated for each country to the intervals obtained using a Normal distribution 
approximation with the CoV for Nigeria. We found good agreement between the approximation and 
full uncertainty analysis for the regions tested (Supplementary Figure 7). We therefore applied this 
approach across all runs using the CoV from the Nigeria simulations and the additional 40 
administrative 1 units to obtain 95% uncertainty intervals across the results for SSA.  
Results are highly sensitive to when mass LLIN campaigns are scheduled to occur. Multiple countries 
have sub-national campaigns and it is unclear where within the country LLINs are due to be 
distributed. To illustrate this uncertainty caused by the timing of LLIN campaigns we conducted a 
sensitivity analysis for countries where the location of mass campaigns are unknown by simulating 
distributions in either in 2019 or 2020 (Supplementary Table 12). 
SMC was assumed to be undertaken in the same administrative units covered in 2019 and 70% of 
children under 5 years of age are assumed treated, except in Senegal where children up to ten years 
old are covered and we assume 70% coverage19. We simulated amodiaquine plus sulfadoxine-
pyrimethamine as the prophylactic drug delivered for SMC campaigns across three or four rounds 
depending on the existing strategy of the country28. The proportion of clinical cases of malaria 
receiving the appropriate prompt treatment outside the COVID-19 epidemic was estimated based on 
data extracted from the DHS on the proportion of febrile children who were given medical treatment, 
and the type of treatment administered (Demographic and Health Surveys, https://dhsprogram.com/ 
(accessed September 10, 2018)). Prior to 1 May 2020, indoor residual spraying was assumed to take 
place annually in the same administrative units covered historically (as per 2018)29. During the period 
of health system interruption SMC and clinical treatment of cases can either reduce to zero, reduce 
to 50% of the planned level (35% of the target age group are covered for SMC), or continue as before. 
Indoor residual spraying of insecticide (IRS) is assumed to be cancelled.  
The distribution of drugs either through existing SMC channels or through special mass drug 
administration (MDA) projects could be used to reduce the impact of COVID-19 on malaria. Bespoke 
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methods of delivery are being considered to deliver drugs to households whilst maintaining social 
distancing. In regions where SMC is carried out, this intervention could be extended from the current 
target age of children under 5 years old to targeting children under 10 or 15 years. All other aspects 
of the SMC campaigns are assumed to remain the same (i.e. regions where it is deployed, seasonal 
timing, number of rounds and coverage within the targeted age group). Outside of regions with SMC, 
a single round of MDA using a drug with a similar profile of prophylactic protection to sulfadoxine-
pyrimethamine plus amodiaquine (in the absence of resistance) is considered. It is assumed to be 
administered to 70% of the population (either under 5 years of age or to all ages) with the timing of 
the MDA aligned for each region to be optimally deployed at the start of the peak transmission season. 
We simulated the number of malaria deaths from 1 May 2020 to 30 April 2021, for both the non-
COVID-19 scenario, and the four COVID-19 scenarios, and for a range of malaria intervention 
combination strategies. Care should be taken when directly comparing the relative impact of different 
malaria interventions as they vary in their period of disruption (other than in the suppression 
scenario). All possible treatment options are considered, although some, such as the halting of all case 
management for a year, are considered unlikely. Projected deaths were aggregated across regions and 
presented as the increase in deaths predicted for the different COVID-19 and malaria scenarios 
relative to the non-COVID-19 scenario for the year. Sub-national differences outside Nigeria should be 
treated with caution. Many countries now have mass LLIN campaigns staggered over multiple years 
for logistical and financial reasons, and this information on sub-national timing of LLIN campaigns were 
unavailable for all countries other than Nigeria which can introduce substantial uncertainty 
(Supplementary Table 12). Similarly, at a local level, the impact of service disruption would be greater 
for clinical treatment where clinics treat a high proportion of the local community relative to clinics 
serving a proportionally lower sample of the community.  
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The impact of the uncertainty in the R0 for COVID-19 in Africa on malaria mortality is investigated for 
Nigeria by assuming the period of service interruption increases from 6 to 9 months which is predicted 
to be required if the COVID-19 R0 reduced from 3.0 to 2.5 (Supplementary Table 6).  
 
Fever in COVID-19 and malaria 
A literature search was conducted to obtain the proportion of fever in COVID-19-positive patients, 
broken down by age and type of cohort. The search terms “covid” OR “SARS-CoV-2” AND “fever” were 
used in the PubMed and MEDLINE (Ovid) databases, yielding 384 non-duplicate records. Titles and 
abstracts of these records were screened for the words “child” or “children”, resulting in 28 hits. 
Nine of the 28 papers were systematic reviews, which were screened for further references. With this, 
36 papers were added for extraction. In all, 64 full texts were screened. Eight papers were rejected as 
they were in Chinese (n = 5) or because they did not provide a breakdown of fever between adults 
and children (n = 3). Data were extracted from 49 papers for this analysis29-78 (Supplementary Table 
13). Each study examines a different cohort of patients which may influence the prevalence of fever. 
Here we classify each cohort into those patients admitted to (i) hospital, (ii) intensive care units (ICU), 
(iii) contacts of known cases, or (iv) a mixed cohort.    
Logistic regression is used to characterise how age influences the prevalence of fever in patients 
confirmed with COVID-19. The reporting of fever increased significantly with age (likelihood ratio test 
p<0.01), though there was no significant difference between the various cohorts examined here 
(however, the number of data points investigating the presence of fever in contacts of known COVID-
19 cases, which is more likely to represent community transmission, were relatively low, Figure 3A). 
The percentage of people with malarial fever and how this varies with age is estimated from our 
malaria transmission dynamics model. Results of both models are then combined assuming the 
prevalence of the two diseases are independent. The malaria model is also used to estimate the 
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proportion of patent infections which are asymptomatic to determine the prevalence of 
asymptomatic malaria cases in COVID-19 infected individuals. 
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